Diagnostic Medical Systems: 2025 Half-Year Results Up

Diagnostic Medical Systems (DMS) has published its 2025 half-year results, marked by a 3% increase in revenue, reaching €23.6 million. EBITDA is up sharply by 82%, with a margin increasing from 4.1% to 7.2%. Net income attributable to equity holders of the parent improved by €1.2 million, remaining slightly negative at €(0.2) million.

Radiology business grew by 5%, while Bone Densitometry declined by 3%. White-label sales increased by 12%, representing 57% of revenue. Sales in North America increased significantly by 194%.

The group maintains a healthy financial position, strengthened post-half by a €6.9 million capital increase. The funds raised are intended to support its Imaging 2027 strategic plan. DMS anticipates accelerated growth in the second half of 2025, despite a less dynamic market environment.